Prevent Gli activation downstream, leading to target gene inhibition and CSC suppression. Most inhibitors in this category are FDA approved to treat BCC, while others are under phase I/II clinical trials to treat breast cancer and medulloblastoma. This evidence concerns the gene GLI1 and skin basal cell carcinoma.